Pfizer Celebrex Polyp Trials Get Added Weight With Vioxx Withdrawal

Two trials for the COX-2 inhibitor Celebrex in prevention of adenomatous polyps take on added significance following Merck's withdrawal of Vioxx

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet